Author:
Ogoshi Kyoji,Mitomi Toshio,Isono Kaichi,Kimura Kouzaburou,Okajima Kunio,Tsuji Kimiyoshi,Sugita Minoru
Publisher
The Japanese Society of Strategies for Cancer Research and Therapy
Subject
Pharmacology (medical),Cancer Research,Oncology
Reference47 articles.
1. 1) Fizazi K, Cojean I, Pignon JP, Rixe O, Gatineau M, Hadef S, Arriagada R, Baldeyrou P, Comoy R, Chevalier TI. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy. An early predictor of complete response and survival in patients with small cell lung carcinoma. Cancer 82: 1049-1055, 1998.
2. 2) Grankvist K, Ljunberg B, Rasmuson T. Evaluation of five glycoprotein tumor markers (CEA, CA-50, CA-19-9, CA-125, CA15-3) for the prognosis of renal-cell carcinoma. Int J Cancer (Pred Oncol), 74: 233-236, 1997.
3. 3) Foekens JA, Portengen H, Look MP, Putten van P, Thirion B, Bontenbal M, Klijin JG. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br J Cancer, 70: 1217-1223, 1994.
4. 4) American Society of Clinical Oncology. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol, 16: 793-795, 1998.
5. 5) Ogoshi K, Mitomi T. Clinical effects of PSK on esophageal and gastric cancer patients and usefulness of serum levels of glycoproteins and HLA antigens as prognostic indicators. J Jpn Surg, 90: 1443-1446, 1989.